{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:19:35Z","timestamp":1792783175436,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Tokyo Women's Medical University","id":[{"id":"https:\/\/ror.org\/03kjjhe36","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05174-5","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T18:32:11Z","timestamp":1778178731000},"page":"4147-4157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2461-0860","authenticated-orcid":false,"given":"Kazutaka","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3834-0153","authenticated-orcid":false,"given":"Kazuhiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1407-2588","authenticated-orcid":false,"given":"Yuki","family":"Kobari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4290-0595","authenticated-orcid":false,"given":"Yuki","family":"Nemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5146-656X","authenticated-orcid":false,"given":"Hiroki","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3009-0146","authenticated-orcid":false,"given":"Hironori","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpei","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Shimmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunobu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2228-4086","authenticated-orcid":false,"given":"Tsunenori","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-0943","authenticated-orcid":false,"given":"Toshio","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"9","key":"5174_CR1","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK et al (2021) Nivolumab plus cabozantinib versus sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 384(9):829\u2013841. https:\/\/doi.org\/10.1056\/NEJMoa2026982. (in eng)","journal-title":"N Engl J Med"},{"issue":"14","key":"5174_CR2","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384(14):1289\u20131300. https:\/\/doi.org\/10.1056\/NEJMoa2035716","journal-title":"N Engl J Med"},{"issue":"12","key":"5174_CR3","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI et al (2019) Pembrolizumab plus axitinib versus sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 380(12):1116\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa1816714. (in eng)","journal-title":"N Engl J Med"},{"issue":"12","key":"5174_CR4","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ et al (2019) Avelumab plus axitinib versus sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 380(12):1103\u20131115. https:\/\/doi.org\/10.1056\/NEJMoa1816047. (in eng)","journal-title":"N Engl J Med"},{"issue":"6","key":"5174_CR5","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.eururo.2025.02.020","volume":"87","author":"A Bex","year":"2025","unstructured":"Bex A et al (2025) European Association of Urology guidelines on renal cell carcinoma: the 2025 update. Eur Urol 87(6):683\u2013696. https:\/\/doi.org\/10.1016\/j.eururo.2025.02.020. (in eng)","journal-title":"Eur Urol"},{"key":"5174_CR6","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0008","author":"RJ Motzer","year":"2024","unstructured":"Motzer RJ et al (2024) NCCN Guidelines\u00ae insights: kidney cancer, version 2.2024. J Natl Compr Canc Netw. https:\/\/doi.org\/10.6004\/jnccn.2024.0008. (in eng)","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"5174_CR7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s11523-024-01096-3","volume":"19","author":"D Santini","year":"2024","unstructured":"Santini D et al (2024) Real-world primary resistance to first-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1). Target Oncol 19(6):893\u2013903. https:\/\/doi.org\/10.1007\/s11523-024-01096-3. (in eng)","journal-title":"Target Oncol"},{"issue":"4","key":"5174_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10147-024-02471-w","volume":"29","author":"H Ishihara","year":"2024","unstructured":"Ishihara H et al (2024) First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data. Int J Clin Oncol 29(4):473\u2013480. https:\/\/doi.org\/10.1007\/s10147-024-02471-w","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"5174_CR9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11523-022-00940-8","volume":"18","author":"H Ishihara","year":"2023","unstructured":"Ishihara H et al (2023) Comparison of the impact of immune-related adverse events due to immune checkpoint inhibitor dual combination therapy and immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy in patients with advanced renal cell carcinoma. Target Oncol 18(1):159\u2013168. https:\/\/doi.org\/10.1007\/s11523-022-00940-8. (in eng)","journal-title":"Target Oncol"},{"issue":"1","key":"5174_CR10","doi-asserted-by":"publisher","first-page":"63.e19","DOI":"10.1016\/j.urolonc.2024.10.015","volume":"43","author":"T Hara","year":"2025","unstructured":"Hara T et al (2025) Comparative prognostic value of tumor volume in IOIO and IOTKI treatment for metastatic renal cancer. Urol Oncol 43(1):63.e19-63.e27. https:\/\/doi.org\/10.1016\/j.urolonc.2024.10.015. (in eng)","journal-title":"Urol Oncol"},{"issue":"11","key":"5174_CR11","doi-asserted-by":"publisher","first-page":"374.e21","DOI":"10.1016\/j.urolonc.2024.06.013","volume":"42","author":"T Yanagisawa","year":"2024","unstructured":"Yanagisawa T et al (2024) First-line therapy for metastatic renal cell carcinoma: a propensity score-matched comparison of efficacy and safety. Urol Oncol 42(11):374.e21-374.e29. https:\/\/doi.org\/10.1016\/j.urolonc.2024.06.013. (in eng)","journal-title":"Urol Oncol"},{"key":"5174_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026. (in eng)","journal-title":"Eur J Cancer"},{"issue":"6","key":"5174_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102458","volume":"23","author":"W Chen","year":"2025","unstructured":"Chen W et al (2025) Comparisons of pembrolizumab plus lenvatinib, nivolumab plus cabozantinib, and cabozantinib monotherapy in advanced non-clear cell renal cell carcinoma based on individual patient data reconstruction. Clin Genitourin Cancer 23(6):102458. https:\/\/doi.org\/10.1016\/j.clgc.2025.102458. (in eng)","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"5174_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211105","volume":"14","author":"SH Kim","year":"2019","unstructured":"Kim SH et al (2019) Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy. PLoS ONE 14(2):e0211105. https:\/\/doi.org\/10.1371\/journal.pone.0211105. (in eng)","journal-title":"PLoS ONE"},{"issue":"1","key":"5174_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3892\/mco.2014.432","volume":"3","author":"S Hamada","year":"2015","unstructured":"Hamada S et al (2015) Clinical characteristics and prognosis of patients with renal cell carcinoma and liver metastasis. Mol Clin Oncol 3(1):63\u201368. https:\/\/doi.org\/10.3892\/mco.2014.432. (in eng)","journal-title":"Mol Clin Oncol"},{"issue":"5","key":"5174_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102994","volume":"9","author":"T Powles","year":"2024","unstructured":"Powles T et al (2024) Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial. ESMO Open 9(5):102994. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102994. (in eng)","journal-title":"ESMO Open"},{"key":"5174_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16172998","author":"T Hilser","year":"2024","unstructured":"Hilser T et al (2024) Cabozantinib plus nivolumab in adult patients with advanced or metastatic renal cell carcinoma: a retrospective, non-interventional study in a real-world Cohort\/GUARDIANS project. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16172998. (in eng)","journal-title":"Cancers (Basel)"},{"issue":"7","key":"5174_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-025-04043-x","volume":"74","author":"M Santoni","year":"2025","unstructured":"Santoni M et al (2025) Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1). Cancer Immunol Immunother 74(7):225. https:\/\/doi.org\/10.1007\/s00262-025-04043-x. (in eng)","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"5174_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1470-2045(23)00049-9","volume":"24","author":"TK Choueiri","year":"2023","unstructured":"Choueiri TK et al (2023) Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol 24(3):228\u2013238. https:\/\/doi.org\/10.1016\/S1470-2045(23)00049-9. (in eng)","journal-title":"Lancet Oncol"},{"key":"5174_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115389","volume":"220","author":"J Gavira","year":"2025","unstructured":"Gavira J et al (2025) Activity of lenvatinib-based therapy in previously treated patients with metastatic renal cell carcinoma: a European multicenter study (LENVA-LAT). Eur J Cancer 220:115389. https:\/\/doi.org\/10.1016\/j.ejca.2025.115389. (in eng)","journal-title":"Eur J Cancer"},{"key":"5174_CR21","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2025.1002305","author":"I Tsimafeyeu","year":"2025","unstructured":"Tsimafeyeu I et al (2025) Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma. Explor Target Antitumor Ther. https:\/\/doi.org\/10.37349\/etat.2025.1002305. (in eng)","journal-title":"Explor Target Antitumor Ther"},{"issue":"12","key":"5174_CR22","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s10147-024-02633-w","volume":"29","author":"T Hara","year":"2024","unstructured":"Hara T et al (2024) Efficacy and safety of lenvatinib and pembrolizumab as first-line treatment for advanced renal cell carcinoma patients: real-world experience in Japan. Int J Clin Oncol 29(12):1931\u20131936. https:\/\/doi.org\/10.1007\/s10147-024-02633-w. (in eng)","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"5174_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-025-04019-x","volume":"74","author":"C Porta","year":"2025","unstructured":"Porta C et al (2025) Pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: real-world evidences from the international ARON- 1 study. Cancer Immunol Immunother 74(7):196. https:\/\/doi.org\/10.1007\/s00262-025-04019-x. (in eng)","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"5174_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.eururo.2023.01.001","volume":"84","author":"MS Ernst","year":"2023","unstructured":"Ernst MS et al (2023) Outcomes for international metastatic renal cell carcinoma database consortium prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma. Eur Urol 84(1):109\u2013116. https:\/\/doi.org\/10.1016\/j.eururo.2023.01.001. (in eng)","journal-title":"Eur Urol"},{"issue":"3","key":"5174_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S1470-2045(14)71222-7","volume":"16","author":"JJ Ko","year":"2015","unstructured":"Ko JJ et al (2015) The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol 16(3):293\u2013300. https:\/\/doi.org\/10.1016\/S1470-2045(14)71222-7. (in eng)","journal-title":"Lancet Oncol"},{"issue":"3","key":"5174_CR26","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.eururo.2021.05.020","volume":"80","author":"J Courcier","year":"2021","unstructured":"Courcier J et al (2021) Primary renal tumour response in patients treated with nivolumab for metastatic renal cell carcinoma: results from the GETUG-AFU 26 NIVOREN trial. Eur Urol 80(3):325\u2013329. https:\/\/doi.org\/10.1016\/j.eururo.2021.05.020. (in eng)","journal-title":"Eur Urol"},{"issue":"2","key":"5174_CR27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11523-022-00866-1","volume":"17","author":"A Markham","year":"2022","unstructured":"Markham A (2022) Cabozantinib plus nivolumab: a review in advanced renal cell carcinoma. Target Oncol 17(2):193\u2013201. https:\/\/doi.org\/10.1007\/s11523-022-00866-1. (in eng)","journal-title":"Target Oncol"},{"issue":"8","key":"5174_CR28","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1093\/jjco\/hyaf070","volume":"55","author":"T Horiuchi","year":"2025","unstructured":"Horiuchi T et al (2025) High real-world incidence of hepatic dysfunction from cabozantinib plus nivolumab for Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 55(8):947\u2013953. https:\/\/doi.org\/10.1093\/jjco\/hyaf070. (in eng)","journal-title":"Jpn J Clin Oncol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05174-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05174-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05174-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:53:16Z","timestamp":1789631596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05174-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["5174"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05174-5","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"28 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Ethics Review Boards of the participating organizations (ID: 2020-0009). The study was conducted in accordance with the principles of the 1964 Declaration of Helsinki and its amendments.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The need for informed consent was waived because of the retrospective observational nature of this study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. (The manuscript does not contain any individual person's data in any form).","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}]}}